Quidel (QDEL) Set to Announce Earnings on Tuesday

Quidel (NASDAQ:QDEL) will be releasing its earnings data after the market closes on Tuesday, November 6th. Analysts expect Quidel to post earnings of $0.40 per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Quidel (NASDAQ:QDEL) last issued its quarterly earnings results on Tuesday, August 7th. The company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.12. The company had revenue of $103.16 million during the quarter, compared to analysts’ expectations of $102.15 million. Quidel had a net margin of 4.63% and a return on equity of 19.39%. On average, analysts expect Quidel to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Shares of QDEL opened at $66.68 on Monday. Quidel has a twelve month low of $33.01 and a twelve month high of $77.63. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.10 and a quick ratio of 0.71. The company has a market cap of $2.60 billion, a PE ratio of -952.57, a price-to-earnings-growth ratio of 1.04 and a beta of 1.05.

In other Quidel news, Director Kenneth F. Buechler sold 5,000 shares of Quidel stock in a transaction on Thursday, August 30th. The shares were sold at an average price of $75.01, for a total transaction of $375,050.00. Following the completion of the transaction, the director now directly owns 53,519 shares of the company’s stock, valued at $4,014,460.19. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Charles P. Slacik sold 1,000 shares of Quidel stock in a transaction on Friday, August 10th. The stock was sold at an average price of $68.28, for a total transaction of $68,280.00. Following the transaction, the director now directly owns 7,820 shares of the company’s stock, valued at $533,949.60. The disclosure for this sale can be found here. Insiders sold 163,667 shares of company stock valued at $11,366,872 over the last three months. 16.70% of the stock is owned by company insiders.

QDEL has been the subject of several analyst reports. TheStreet cut shares of Quidel from a “b” rating to a “c+” rating in a research note on Wednesday, August 8th. Canaccord Genuity raised their target price on shares of Quidel from $78.00 to $80.00 and gave the company a “buy” rating in a research note on Monday, September 10th. Zacks Investment Research cut shares of Quidel from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 10th. BidaskClub raised shares of Quidel from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, September 5th. Finally, Barclays raised their target price on shares of Quidel from $65.00 to $78.00 and gave the company an “overweight” rating in a research note on Monday, August 6th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $74.86.

About Quidel

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus products point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye.

See Also: Understanding each part of a balance sheet

Earnings History for Quidel (NASDAQ:QDEL)

Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply